| epirubicin / Generic mfg. |
RC48-C024, CTR20231476: A randomized, open-label, multicenter phase II clinical study evaluating the efficacy and safety of vedicitumab alone or in combination with toripalimab or sequential chemotherapy in patients with HR-negative, HER2-low breast cancer |
|
|
| Ongoing | 2 | | China | Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, carboplatin - Generic mfg., epirubicin - Generic mfg., cyclophosphamide - Generic mfg. | Remegen Biopharmaceutical (Yantai) Co., Ltd | HR-negative, HER2-low breast cancer | | | | |
| Completed | 2 | 36 | Europe | Pegfilgrastim, Neupogen, Ratiograstim, Zarzio, Dactinomycin, Cosmegen Lyovac, Methotrexate, Etoposide, Etopophos, Cisplatin, Epirubicin | Queen Mary University of London | Testicular Neoplasms | 06/13 | 01/14 | | |
ACTRN12616000786493: Phase II study of Paclitaxel and Epirubicin as Neoadjuvant Treatment for locally advanced Breast Cancer. |
|
|
| Active, not recruiting | 2 | 40 | | | The Queen Elizabeth Hospital, Bristol-Myers Squibb Pty Ltd, The Queen Elizabeth Hospital | Breast Cancer | | | | |
NCT00806949: Epirubicin, Oxaliplatin, and Capecitabine or Docetaxel and Oxaliplatin in Treating Patients With Advanced Esophageal Cancer, Gastroesophageal Junction Cancer, or Stomach Cancer |
|
|
| Recruiting | 2 | 140 | Europe | capecitabine, docetaxel, epirubicin hydrochloride, oxaliplatin | All Ireland Cooperative Oncology Research Group | Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer | 12/09 | | | |
JONIE, R000003949: Randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with primary breast cancer |
|
|
| Recruiting | 2 | 180 | Japan | paclitaxel - Generic mfg., zoledronic acid - Generic mfg., epirubicin - Generic mfg., 5-fluorouracil - Generic mfg., cyclophosphamide - Generic mfg. | JONIE Study Group | Breast Cancer | | | | |
ChiCTR-TRC-10001057: The Clinical Research of the Intermediate and Advanced Hepatoma Treated by Cinobufacin by Perfusion |
|
|
| Completed | 2 | 284 | | Treatment group: cinobufotalin injection 60ml+40% LIP 5-20ml obstructed ;Control group: Epirubicin 40mg+40% Lipiodol 5-20ml blocked | Department of TCM, Changhai Hospital of Shanghai; Level of the institution：, self-financing | Intermediate and Advanced Hepatoma | | | | |
NCT01330212: PET-Guided Chemotherapy and Hormone Therapy in Treating Women With Previously Untreated Invasive Breast Cancer |
|
|
| Recruiting | 2 | 60 | US | bevacizumab, trastuzumab, capecitabine, cyclophosphamide, docetaxel, epirubicin hydrochloride, vinorelbine tartrate, gene expression analysis, microarray analysis, neoadjuvant therapy, positron emission tomography, therapeutic conventional surgery | Auxilio Mutuo Cancer Center | Breast Cancer | 03/13 | | | |
2012-004489-17: Clinical study for elderly or unfit for a 3-weekly chemotherapy regimen women, with early breast cancer, to evaluate the efficacy of weekly nab-paclitaxel (Abraxane®) treatment versus weekly epirubicin standard treatment. Studio clinico per donne anziane o non candidate ad assumere trattamento chemioterapico trisettimanale, operate di tumore mammario, che confronta la efficacia di un trattamento settimanale con nab-paclitaxel (Abraxane®) verso trattamento settimanale standard con epirubicina. |
|
|
| Ongoing | 2 | 330 | Europe | , Concentrate for solution for infusion, ABRAXANE, Epirubicina | ISTITUTO EUROPEO DI ONCOLOGIA, Celgene, Veronesi Foundation | early breast cancer in elderly patients or patients who are unfit for a polychemotherapy regimen, early breast cancer in elderly patients or patients who are unfit for a polychemotherapy regimen, Diseases [C] - Cancer [C04] | | | | |
2013-001226-25: A phase II randomized, open-label neo-adjuvant study of standard chemotherapy regimen compared to high dose chemotherapy regimen with autologous stem cell transplantation in patients with triple negative breast cancer Studio di Fase II, in aperto, in neo-adiuvante, randomizzato con regime chemioterapico classico rispetto al regime di chemioterapia ad alte dosi con trapianto autologo di cellule staminali nei pazienti con carcinoma mammario triplo negativo |
|
|
| Ongoing | 2 | 74 | Europe | Epirubicin, Cyclophosphamide, Docetaxel, THIOTEPA, Powder and solvent for solution for injection/infusion, Powder for injection, Concentrate for solution for infusion, Powder for concentrate for solution for infusion | ISTITUTI OSPITALIERI DI CREMONA, Fondazione FIRM Onlus | Triple Negative Breast Cancer patients with breast tumor >2,5 cm, no, Diseases [C] - Cancer [C04] | | | | |
NCT01740271: A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients |
|
|
| Recruiting | 2 | 48 | Canada | Epirubicin | AHS Cancer Control Alberta | Breast Neoplasms | 06/15 | 06/25 | | |
NCT01340430 / 2010-021600-24: Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer |
|
|
| Completed | 2 | 43 | Europe | Trastuzumab, herceptin | Lucia Del Mastro,MD | HER-2 Positive Breast Cancer | 12/15 | 01/22 | | |
2008-000657-35: A multi-centre phase II trial to assess the efficacy of epirubicin, cisplatin and capecitabine incorporating the prospective validation of molecular classifiers and exploratory metabonomics. |
|
|
| Ongoing | 2 | 57 | Europe | Cisplatin, Capecitabine, Epirubicin, 154361-50-6, | Greater Glasgow and Clyde Health Board (GGCHB)/University of Glasgow | Metastatic Carcinomas of Unknown Primary origin (CUP) | | | | |
2008-002715-40: NEOADJUVANT EPIRUBICIN-OXALIPLATIN-XELODA AND OXALIPLATIN-XELODA-RADIOTHERAPY IN LOCALLY ADVANCED, RESECTABLE, GASTRIC CANCER. A PHASE II COLLABORATIVE STUDY |
|
|
| Ongoing | 2 | 49 | Europe | FARMORUBICINA, ELOXATIN*INFUS 1FL 20ML 5MG/ML, XELODA*60CPR RIV 150MG, XELODA*120CPR RIV 500MG, FARMORUBICINA, ELOXATIN*INFUS 1FL 20ML 5MG/ML, XELODA*60CPR RIV 150MG, XELODA*120CPR RIV 500MG | CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO | PATIENTS WITH OPERABLE GASTRIC ADENOCARCINOMA | | | | |
2007-003466-18: PHASE II TRIAL OF PRIMARY CHEMOTHERAPY WITH TRASTUZUMAB IN COMBINATION WITH DOCETAXEL FOLLOWED BY EPIRUBICIN-CYCLOPHOSPHAMIDE IN PATIENTS WITH HER2-OVEREXPRESSING OPERABLE BREAST CANCER |
|
|
| Ongoing | 2 | 42 | Europe | HERCEPTIN, FARMORUBICINA, TAXOTERE, ENDOXAN BAXTER, HERCEPTIN, FARMORUBICINA, TAXOTERE, ENDOXAN BAXTER | ISTITUTI FISIOTERAPICI OSPITALIERI | Primary chemotherapy in Her2-overexpressing operable breast cancer patient | | | | |
2009-012048-18: �Fase II study with epirubicin, cisplatin and infusional fluorouracil (ECF) followed by weekly paclitaxel plus metronomic cyclophosphamide � trastuzumab as preoperative treatment of locally advanced ER and PgR negative breast cancer�. |
|
|
| Ongoing | 2 | 64 | Europe | ENDOXAN BAXTER*50CPR RIV 50MG, HERCEPTIN, ENDOXAN BAXTER*50CPR RIV 50MG, HERCEPTIN | ISTITUTO EUROPEO DI ONCOLOGIA | Locally advanced breast cancer | | | | |
2008-006381-29: Neoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene signature in patients with primary breast cancer |
|
|
| Ongoing | 2 | 200 | Europe | Docetaxel, 5-Fluorouracil, Cyclophosphamide, Epirubicin, Taxotere, Fluorouracil, Endoxan, Farmorubicin, Taxotere, Fluorouracil, Endoxan, Farmorubicin | Universitätsmedizin Mainz | Eligible will be only females between 18 - 70 years of age, suffering from histologically confirmed primary breast cancer, nodal status positive or negative, phase cT2, cT3, or cT4 including inflammatory disease. Metastatic disease is excluded. All patients will be treated with 3 cycles Docetaxel and 3 cycles FEC. | | | | |
2010-018389-22: A randomized, multicentre, open-label, Phase II study of the efficacy and safety of lapatinib plus epirubicin and cyclophosphamide (EC90-L) followed by weekly paclitaxel and lapatinib (PX-L) compared with EC90 followed by weekly paclitaxel and trastuzumab (PX-T), as neoadjuvant therapy in patients with previously untreated ErbB2-overexpressing Stage I - IIIA invasive breast cancer with primary tumour size > 1cm. |
|
|
| | 2 | 35 | Europe | Lapatinib, Trastuzumab, GW572016, Tyverb, Herceptin, Tyverb, Herceptin | GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, S.A. | patients with previously untreated ErbB2-overexpressing Stage I - IIIA invasive breast cancer with primary tumour size > 1cm. | | 01/11 | | |
| Ongoing | 2 | 25 | Europe | Epirubicin, 24782, Epirubicin, Epirubicin | Odense University Hospital, The danish cancer society | TOP2A gene amplified and oxaliplatin refractory metastatic colorectal cancer | | | | |
2008-003064-19: Phase-IIb-Study to Evaluate the Effect of a Neoadjuvant Chemotherapy with Docetaxel, Epirubicine and Cyclphosphamide (TEC) in Patients with primary HER-2 neu Negative Mammacarcinoma Phase-IIb-Studie zur Erfassung der Effektivität einer neoadjuvanten Chemotherapie mit Docetaxel, Epirubicin und Cyclophosphamid (TEC) bei Patientinnen mit primärem HER- 2 neu negativem Mammakarzinom Phase-IIb-Studie zur Erfassung der Effektivität einer neoadjuvanten Chemotherapie mit Docetaxel, Epirubicin und Cyclophosphamid (TEC) bei Patientinnen mit primärem HER- 2 neu negativem Mammakarzinom |
|
|
| Ongoing | 2 | 150 | Europe | Epirubicin, Docetaxel, Cyclophosphamid, | Universität Leipzig, Sanofi-Aventis, Amgen | Primary mamma carcinoma Brustkrebs | | | | |
ChiCTR-TRC-14004142: An investigator initiated, open label, prospective, randomized phase II study to compare the efficacy and safety of Paclitaxel plus Epirubicin with Paclitaxel plus Carboplatin as new adjunctive therapy on patients with local advanced breast cancer |
|
|
| Recruiting | 2 | 100 | | Paclitaxel plus Epirubicin ;Paclitaxel plus Epirubicin | Cancer Hospital, Chinese Academy of Medical Sciences ; Level of the institution：, research | Breast Cancer | | | | |
| Active, not recruiting | 2 | 100 | Europe | epirubicin/docetaxel sequential, Farmorubicin (Pfizer) | University of Bergen, Haukeland University Hospital | Stage III Breast Cancer AJCC V7 | 05/16 | 05/26 | | |
NeoTOP, NCT02339532: Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status |
|
|
| Active, not recruiting | 2 | 86 | Europe | FEC100, Docetaxel, Trastuzumab, Pertuzumab, Carboplatin | UNICANCER | Breast Cancer | 10/19 | 06/24 | | |
NCT03839550: Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection |
|
|
| Not yet recruiting | 2 | 200 | RoW | Apatinib Mesylate +SHR-1210, Hepatic Arterial Infusion(HAI) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Hepatocellular Carcinoma | 02/20 | 02/23 | | |
| Active, not recruiting | 2 | 200 | Europe | Neoadjuvant tamoxifen + goserelin (premenopausal women), Neoadjuvant letrozole (postmenopausal women), Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone), Neoadjuvant docetaxel + cyclophosphamide, Neoadjuvant docetaxel, Neoadjuvant docetaxel + trastuzumab + pertuzumab, Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab, Neoadjuvant olaparib, Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone), Breast conserving surgery or mastectomy + SNB/axillary dissection, Postoperative radiotherapy breast/chest wall + regional lymph nodes, Adjuvant trastuzumab, Adjuvant letrozole (postmenopausal women), Adjuvant tamoxifen + goserelin (premenopausal women), Adjuvant palbociclib (if palbociclib given neoadjuvant), Adjuvant Epirubicin+ Cyclophosphamide | Haukeland University Hospital, Helse Vest, Pfizer, AstraZeneca | Breast Cancer | 06/20 | 06/30 | | |
PH002-TP-II, NCT03272477 / 2016-005157-21: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients |
|
|
| Completed | 2 | 257 | Europe | Perjeta Injectable Product, Pertuzumab, Herceptin, Trastuzumab, Tamoxifen, Paclitaxel, Epirubicin, Cyclophosphamide, Anastrozole, Letrozole, Exemestane, Leuprorelin acetate, Goserelin, Leuporelin acetate, Biopsy, Surgery | Palleos Healthcare GmbH, Roche Pharma AG, WSG WOMEN´S HEALTHCARE STUDY GROUP, Cankado GmbH | Breast Neoplasms | 07/20 | 03/24 | | |
ChiCTR1800018964: A single-center, prospective, controlled study of the efficacy and safety of irinotecan or epirubicin in the treatment of unresectable hepatocellular carcinoma via drug-loaded microspheres with transcatheter arterial chemoembolization (DEB-TACE) |
|
|
| Not yet recruiting | 2 | 50 | | Drug-loaded irinotecan microsphere ;epirubicin embolization microspheres | Shaanxi Cancer Hospital; None, self-raised | hepatocellular carcinoma | | | | |
PRETTY, NCT04255056: Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab |
|
|
| Not yet recruiting | 2 | 27 | RoW | Pyrotinib, epirubicin, cyclophosphamide | Sun Yat-sen University | Breast Cancer | 02/21 | 02/25 | | |
NCT02315196: Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer |
|
|
| Active, not recruiting | 2 | 62 | US | pegylated liposomal doxorubicin hydrochloride, CAELYX, Dox-SL, DOXIL, doxorubicin hydrochloride liposome, LipoDox, epirubicin hydrochloride, 4'-epi-doxorubicin HCl, 4'-epiadriamycin, carboplatin, Carboplat, CBDCA, JM-8, Paraplat, Paraplatin, therapeutic conventional surgery, paclitaxel, Anzatax, Asotax, TAX, Taxol, laboratory biomarker analysis, quality-of-life assessment, quality of life assessment | Rutgers, The State University of New Jersey, National Cancer Institute (NCI), Rutgers Cancer Institute of New Jersey | Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer | 02/21 | 07/41 | | |
| Active, not recruiting | 2 | 65 | Europe | Trastuzumab IV, Herceptin-150 mg, Trastuzumab SC, Herceptin-600 mg/5 mL, Pertuzumab, PerJeta 420 mg, Docetaxel, Docetaxel 20 MG/ML | Gruppo Oncologico Italiano di Ricerca Clinica, University Hospital of Parma: Department of Biomedical, Biotechnological and Translational Sciences, Pathological Anatomy and Histology Unit, University Hospital of Parma:Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology, University Hospital of Parma:Statistica medica ed epidemiologia clinica-UO Ricerca e Innovazione, Clirest s.r.l., Mipharm SpA, Arithmos srl, Temas srl | Cancer, Breast | 03/21 | 11/21 | | |
NCT04676997: Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC) |
|
|
| Recruiting | 2 | 20 | RoW | Camrelizumab, Nab paclitaxel, Epirubicin, Cyclophosphamide | Shandong Cancer Hospital and Institute, Jiangsu HengRui Medicine Co., Ltd. | Triple Negative Breast Cancer | 07/21 | 02/24 | | |
2018-004457-24: PREDIX II HER2 - improving preoperative treatment of HER2 amplified breast cancer |
|
|
| Not yet recruiting | 2 | 190 | Europe | Herceptin, Tecentriq, Kadcyla, Docetaxel, Carboplatin, Epirubicin, Cyclophosphamide, Pertuzumab, Paklitaxel, Solution for injection, Solution for infusion, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for injection/infusion, Herceptin, Tecentriq, Kadcyla | Karolinska University Hospital, Karolinska University Hospital | Primary breast cancer, Newly diagnosed HER2 amplified breast cancer, Diseases [C] - Cancer [C04] | | | | |
NCT04499118: AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer |
|
|
| Not yet recruiting | 2 | 100 | RoW | AT regimen, Anthracycline/Paclitaxel, TP regimen, Paclitaxel/Platinum | Sichuan Provincial People's Hospital | HER2-negative Breast Cancer | 08/21 | 08/21 | | |
CHIMOVIP, NCT03025477: Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer |
|
|
| Recruiting | 2 | 84 | Europe | CC0 - Carboplatin (IV) - Paclitaxel (IV), CC0 - Cisplatin (IP) - Epirubicin (IV), CC>0 - Carboplatin (IV)- Paclitaxel (IV), CC>0 - Cisplatin (IP/IV)- Epirubicin (IV) | Groupe Hospitalier Diaconesses Croix Saint-Simon, GERCOR - Multidisciplinary Oncology Cooperative Group | Ovarian Cancer, Epithelial | 10/21 | 10/32 | | |
ChiCTR1900024928: Efficacy and safety of Anlotinib plus Epirubicin civ followed by Anlotinib sequential therapy in the first-line chemotherapy for advanced soft tissue sarcoma (STS): A single-arm phase 2 clinical trial |
|
|
| Not yet recruiting | 2 | 30 | | An+EPI→An | Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Self-funding | Sarcoma | | | | |
NCT06470464: Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor |
|
|
| Completed | 2 | 20 | RoW | Thalidomide combined with TGA chemotherapy (nab-paclitaxel + gemcitabine+ epirubicin) | Shandong First Medical University | Germ Cell Tumor, Yolk Sac Tumor | 06/24 | 06/24 | | |
NCT04498793: Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 55 | RoW | Tislelizumab, Nab paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, First Affiliated Hospital Xi'an Jiaotong University, Wuhan Union Hospital, China, Beijing Huanxing Cancer Hospital | HER2-negative Breast Cancer | 12/21 | 12/22 | | |
2021-002300-12: Evaluation of safety of low dose epirubicin in patients with Sepsis and septic shock. Beurteilung der Sicherheit von niedrig dosiertem Epirubicin bei Patienten mit Sepsis und septischem Schock. |
|
|
| Not yet recruiting | 2 | 45 | Europe | Concentrate for solution for infusion, Epirubicin 50 mg HEXAL® Injektionslösung | Friedrich Schiller University, Bundesministerium für Bildung und Forschung (BMBF) | Adult (≥ 18 years) patients admitted to the ICU or IMC with sepsis or septic shock, diagnosed within the previous 24 hours. Erwachsene (≥ 18 Jahre) Patienten die mit Sepsis oder septischem Schock, diagnostiziert innerhalb der letzten 24 Stunden, auf die Intensivstation (ICU)/Überwachungsstation (IMC) eingeliefert werden., patients with severe infection and concomitant organ dysfunction Patienten mit schwerer Infektion und begleitender Funktionsstörung von Organen, Diseases [C] - Bacterial Infections and Mycoses [C01] | | | | |
TREND, ChiCTR2000035262: Neoadjuvant Phase II Study of Tislelizumab combined with chemotherapy in Triple Negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 65 | China | Tislelizumab | Liaoning Province Cancer Hospital ; Liaoning Province Cancer Hospital, BeiGene Shenzhou (Beijing) Biotechnology Co., Ltd. | Breast cancer | | | | |
NCT05213637: Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection |
|
|
| Recruiting | 2 | 430 | RoW | Expanded Activated Lymphocytes (EAL), transarterial chemoembolization (TACE) | Chinese PLA General Hospital, Immunotech Applied Science Ltd. | Hepatocellular Carcinoma (HCC) | 06/22 | 04/23 | | |
NCT04174781: Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC |
|
|
| Active, not recruiting | 2 | 61 | RoW | Sintilimab, Immunotherapy, Anti-PD-1 therapy, DEB-TACE, Drug-eluting Bead Transarterial Chemoembolization | Zhejiang University | Hepatocellular Carcinoma | 07/22 | 12/22 | | |
NeoATCT, NCT04914390: A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer |
|
|
| Recruiting | 2 | 32 | RoW | AT regimen, Anthracycline/Nab-paclitaxel, Tislelizumab, BGB-A317, Anlotinib, AL3818 | Sichuan Provincial People's Hospital | Triple-negative Breast Cancer | 03/25 | 09/25 | | |
NCT04490694: TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma |
|
|
| Enrolling by invitation | 2 | 54 | RoW | Lenvatinib, Lenvatinib treatment, TACE, Transcatheter arterial chemoembolization | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 08/22 | 08/23 | | |
NCT05204524: Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma |
|
|
| Recruiting | 2 | 28 | RoW | Temozolomide for injection combined with epirubicin | Chinese Academy of Medical Sciences | Leiomyosarcoma | 08/22 | 08/23 | | |
| Recruiting | 2 | 120 | RoW | Chemotherapy | Shenzhen People's Hospital | Breast Neoplasms | 08/22 | 12/22 | | |
NeoTENNIS, NCT04418154: Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients |
|
|
| Active, not recruiting | 2 | 70 | RoW | epirubicin hydrochloride, Cyclophosphamide, Albumin bound paclitaxel, Toripalimab | Fudan University | Triple Negative Breast Cancer | 09/22 | 12/25 | | |
NCT01210768: A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients |
|
|
| Active, not recruiting | 2 | 254 | RoW | Epirubicin+Cyclophosphamide, liposomal-doxorubicin+Cyclophosphamide | TTY Biopharm | Breast Cancer | 10/22 | 10/22 | | |
2019-002364-27: A study to assess atezolizumab in combination with dual HER2 blockade plus epirubicin as neoadjuvant therapy for HER2-positive early breast cancer |
|
|
| Not yet recruiting | 2 | 58 | Europe | Atezolizumab, Pertuzumab, Herceptin, RO5541267/F03, RO4368451, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Tecentriq, Perjeta, Herceptin | ABCSG (Austrian Breast & Colorectal Cancer Study Group), Roche Austria GmbH | HER2-positive early breast cancer, Early diagnosed with breast cancer that is HER2-positive, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 1460 | Europe | AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, ARRY-142866, Vandetanib, CAPRELSA, Bicalutamide, Casodex, Olaparib, Lynparza, Anthracyclines, Doxorubicin, Epirubicin, liposomal doxorubicin, Taxanes, paclitaxel, docetaxel, cyclophosphamide, Novatrex, Imeth, DNA intercalators, capecitabine, 5-FU, gemcitabine, Methotrexate, vinca alkaloids, vinorelbine, vinblastine, vincristine, Platinum based chemotherapies, Platinum, carboplatin, cisplatin, Bevacizumab, Avastin, Mitomycin C, Ametycine, Eribulin, Halaven, MEDI4736 | UNICANCER, Fondation ARC, AstraZeneca | Metastatic Breast Cancer | 12/22 | 12/24 | | |
NCT04398914: Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer |
|
|
| Active, not recruiting | 2 | 216 | RoW | Pyrotinib, Trastuzumab, Pertuzumab, Nab-paclitaxel, EC chemotherapy, Physician's choice, T-DM1, Surgery | Shanghai Jiao Tong University School of Medicine, Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer Invasive | 12/22 | 12/27 | | |
| Recruiting | 2 | 42 | RoW | Epirubicin, Pharmorubicin, Taxol, Paraplatin, Cytoxan, Cyclophosphamide, Paclitaxel, Carboplatin, Carboplat | University College Hospital, Ibadan, Lagos State University, Obafemi Awolowo University Teaching Hospital, University of Chicago, University of Lagos, Nigeria, University of Ibadan | Triple Negative Breast Cancer | 03/23 | 08/23 | | |
NCT04899570: Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 20 | RoW | Zanubrutinib, BRUKINSA, Rituximab, Rituxan, Cyclophosphamide, Epirubicin, Vindesine, Prednisone | Peking Union Medical College Hospital | Intravascular Large B-Cell Lymphoma | 04/23 | 04/25 | | |
PILHLE-001, NCT05165225: Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial |
|
|
| Active, not recruiting | 2 | 48 | RoW | Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer, HER2-low-expressing Breast Cancer, Hormone Receptor-positive Breast Cancer, Neoadjuvant Therapy | 09/23 | 03/28 | | |
NCT05400993: Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC |
|
|
| Recruiting | 2 | 59 | RoW | Chidamide, pharmorubicin, Cyclophosphamide, Docetaxel | Shengjing Hospital | Breast Cancer | 05/23 | 05/24 | | |
NCT04717531: Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Pyrotinib, B, Trastuzumab, H, Pertuzumab, P, Docetaxel, T, Epirubicin, E, Cyclophosphamide, C | The First Affiliated Hospital with Nanjing Medical University | Breast Cancer | 06/23 | 05/24 | | |
NCT05483439: A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer |
|
|
| Recruiting | 2 | 100 | RoW | cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin), anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab), traditional herbal medicine | Shengjing Hospital | Stage II-III Breast Cancer | 07/23 | 07/23 | | |
NCT06227117: Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer |
|
|
| Recruiting | 2 | 120 | RoW | Disitamab Vedotin Injection （18 weeks）, DV,RC48-ADC, Toripalimab （18weeks）, JS001, Carboplatin, Disitamab Vedotin Injection （12 weeks）, Sequential Epirubicin, Epirubicin, Sequential CTX, CTX, cyclophosphamide, Toripalimab （12weeks） | RemeGen Co., Ltd. | Breast Cancer | 12/25 | 12/26 | | |
| Active, not recruiting | 2 | 416 | Europe | Atezolizumab 840 MG in 14 ML Injection, Tecentriq, Atezolizumab 1200 MG in 20 ML Injection, Carboplatin, Paclitaxel, Epirubicin, Cyclophosphamide, Biopsy Arm A, Biopsy Arm B, Surgery | Palleos Healthcare GmbH, Roche Pharma AG, Phaon Scientific GmbH, University Hospital, Essen, University Hospital Erlangen | Triple-negative Breast Cancer | 07/23 | 08/24 | | |
2018-000406-36: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study (VESTIGE) |
|
|
| Not yet recruiting | 2 | 240 | Europe | nivolumab, ipilimumab, CISPLATIN, CAPECITABINE, Fluorouracil, EPIRUBICIN, Oxaliplatin, LEUCOVORIN, Docetaxel, L01XC11, Concentrate for solution for infusion, Film-coated tablet, Opdivo, Yervoy | European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for the Research and Treatment of Cancer, BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION | Gastric, lower esophageal or GE-junction adenocarcinoma, Stomach cancer and cancer of the lower part of the esophageus, Diseases [C] - Cancer [C04] | | | | |
NeoSACT, NCT04877821: The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC |
|
|
| Recruiting | 2 | 31 | RoW | Sintilimab, Anlotinib, Nab paclitaxel, Carboplatin, Epirubicin, Cyclophosphamide | Guangdong Provincial People's Hospital | Triple Negative Breast Cancer | 08/23 | 12/25 | | |
NCT05444998: Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for HER2+Breast Cancer |
|
|
| Not yet recruiting | 2 | 20 | NA | Intuzumab, pyrrolidone, nab-paclitaxel | Xijing Hospital | Breast Cancer | 08/23 | 12/23 | | |
| Active, not recruiting | 2 | 156 | RoW | Doxorubicin liposome, PLD, Cyclophosphamide, CTX, Trastuzumab, Herceptin, Docetaxel, Taxotere, Epirubicin, EPI, Pertuzumab, Paclitaxel, Paclitaxel-albumin | Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer, Neoadjuvant Chemotherapy | 09/23 | 09/26 | | |
NCT04214626: R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 60 | RoW | Rituximab, RiTUXimab Injection, Lenalidomide, Lenalidomide capsule, Cyclophosphamide, Cyclophosphamide Injection, Epirubicin, Epirubicin hydrochloride, Vincristine, Vincristine Injection, Prednisone, Prednisone Oral Product, Methotrexate, Methotrexate Injectable Solution | Henan Cancer Hospital | Diffuse Large B Cell Lymphoma | 11/23 | 01/25 | | |
NCT06140966: Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma |
|
|
| Recruiting | 2 | 54 | RoW | Daratumumab, Darzalex, Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone, Baycadron, Cisplatin, Platinol, epirubicin, Pharmorubicin, Cyclophosphamide, Cytoxan, Etoposide, Eposin, Melphalan, Alkeran, ASCT, autologous stem cell transplantation, bortezomib, Velcade | Wuhan Union Hospital, China | Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma | 10/26 | 10/27 | | |
| Recruiting | 2 | 52 | RoW | Azacitidine in combination with R-CHOP | The First Affiliated Hospital of Xiamen University, Jiangsu Provincial People's Hospital, Sun Yat-sen University, Chinese Academy of Medical Sciences, Shanxi Province Cancer Hospital | DLBCL - Diffuse Large B Cell Lymphoma, TP53 | 05/25 | 05/25 | | |
NCT04067037: Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 60 | RoW | Camrelizumab, SHR-1210, Epirubicin, Epirubicin hydrochloride, Vincristine, Oncovin, Dacarbazine | Henan Cancer Hospital | Classical Hodgkin Lymphoma | 06/24 | 12/24 | | |
NCT04433156: VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma |
|
|
| Recruiting | 2 | 60 | RoW | Bortezomib, Bortezomib Injection, Rituximab, RiTUXimab Injection, Epirubicin, Epirubicin hydrochloride, Cyclophosphamide, Cyclophosphamide Injection, Prednisone, Prednisone Oral Product | Henan Cancer Hospital | Marginal Zone Lymphoma | 12/23 | 04/25 | | |
| Not yet recruiting | 2 | 49 | RoW | Sintilimab | First Affiliated Hospital, Sun Yat-Sen University | Triple Negative Breast Cancer | 12/23 | 03/24 | | |
ChiCTR1800020217: A prospective, open, multicenter, clinical trial for epirubicin, cyclophosphamide, and pyrotinib, sequential docetaxel plus trastuzumab and pyrotinib in the treatment of HER2-positive breast cancer |
|
|
| Recruiting | 2 | 60 | | EC+Pyrotinib→TH+Pyrotinib ;EC→TH | The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University, self-financing | Breast cancer | | | | |
NCT04668365: Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma |
|
|
| Recruiting | 2 | 59 | RoW | Rituximab, RiTUXimab Injection, Zanubrutinib, Zanubrutinib Pill, Cyclophosphamide, Cyclophosphamide Injection, Epirubicin, Epirubicin Injection, Vincristine, Vincristine Injection, Prednisone, Prednisone Pill | Henan Cancer Hospital | Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation | 12/23 | 12/25 | | |
HIFU, NCT05491694: To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After Induction in the Treatment of Early Triple-negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 20 | NA | Toripalimab, Epirubicin, High Intensity Focused Ultrasoun, Cyclophosphamide, Carboplatin, Nab-paclitaxel | The First Affiliated Hospital with Nanjing Medical University | Breast Cancer, TNBC - Triple-Negative Breast Cancer | 12/23 | 12/24 | | |
NCT04872985: Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial |
|
|
| Recruiting | 2 | 140 | RoW | Pyrotinib, Epirubicin, E, Doxorubicin Hydrochloride Liposome Injection, A, Cyclophosphamide, C, Docetaxel, T, Nab paclitaxel, Placebo | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer, Hormone-receptor Positive Breast Cancer | 12/23 | 12/28 | | |
NCT05447702: Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) |
|
|
| Recruiting | 2 | 35 | RoW | Camrelizumab, Apatinib, Nab-paclitaxel, Epirubicin, Cyclophosphamide | West China Hospital, Jiangsu HengRui Medicine Co., Ltd. | Triple Negative Breast Cancer | 12/23 | 12/26 | | |
NCT05681728: A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer |
|
|
| Recruiting | 2 | 26 | RoW | Pembrolizumab, Paclitaxel, Epirubicin, Cyclophosphamide | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Breast Cancer | 02/24 | 06/24 | | |
NCT06389006: To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer |
|
|
| Recruiting | 2 | 79 | RoW | Disitamab Vedotin for Injection, RC48, Toripalimab, JS001, Epirubicin, Cyclophosphamide, CTX | RemeGen Co., Ltd. | Breast Cancer | 06/25 | 12/26 | | |
| Not yet recruiting | 2 | 76 | NA | QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Albumin-bound paclitaxel, Doxorubicin, Cyclophosphamide, Epirubicin | Fudan University | Early Breast Cancer, Neoadjuvant Therapy, HR+HER2- Breast Cancer | 11/25 | 11/30 | | |
NCT05290090: ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL |
|
|
| Recruiting | 2 | 31 | RoW | Rituximab, Lenalidomide, Zanubrutinib and RCHOP, BGB-3111 | Zhejiang Cancer Hospital | Diffuse Large B Cell Lymphoma | 06/24 | 12/25 | | |
TARMAC, NCT06291064: Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 85 | NA | Cyclophosphamide, Epirubicin, Docetaxel, Carboplatin, Breast Surgery, Capecitabine | University of Chicago | Triple Negative Breast Cancer | 06/29 | 06/32 | | |
KEYPARTNER, NCT06371807: Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab |
|
|
| Not yet recruiting | 2 | 20 | Europe | Pembrolizumab injection, Doxorubicin or Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin | Fundacao Champalimaud | Early Breast Cancer, Triple Negative Breast Cancer | 07/25 | 12/26 | | |
| Recruiting | 2 | 45 | Europe | Epirubicin, Placebo | Jena University Hospital, Ruhr University of Bochum, University Medicine Greifswald | Sepsis | 10/24 | 12/24 | | |
NCT05887726: Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors |
|
|
| Not yet recruiting | 2 | 30 | RoW | Zanubrutinib, Rituximab, Cyclophosphamide, Epirubicin, Vincristine, Prednisone | Liaoning Tumor Hospital & Institute | Diffuse Large B Cell Lymphoma | 08/24 | 08/25 | | |
NJMU- BC03, NCT06470633: To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer |
|
|
| Not yet recruiting | 2 | 29 | NA | Adebrelimab, PD-Li, High Intensity Focused Ultrasoun（HIFU）, Cyclophosphamide, Epirubicin, Docetaxel | The First Affiliated Hospital with Nanjing Medical University, Jiangsu Hengrui Pharmaceuticals Co.,Ltd | Breast Cancer, HR+/HER2- Breast Cancer | 06/26 | 12/26 | | |
NCT05572983: Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype |
|
|
| Recruiting | 2 | 47 | RoW | Chidamide combined with CHOP, Induction treatment, Chidamide, Maintenance treatment | Sun Yat-sen University | Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype | 09/24 | 09/26 | | |
| Not yet recruiting | 2 | 28 | Europe | Epirubicin, Mitomycin, Gemcitabine, Docetaxel | University of Bern, Spitalzentrum Biel | Bladder Cancer, Non-muscle Invasive Bladder Cancer, Low-risk | 10/26 | 10/29 | | |
NCT05816694: The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train. |
|
|
| Not yet recruiting | 2 | 50 | RoW | NAB-Paclitaxel plus Cisplatin, Cisplatin plus Epirubicin plus Cyclophosphamide | Peng Liu | Histological or Cytological Confirmed Stage Ⅲ and Ⅳa Thymoma | 10/24 | 04/26 | | |
NCT05024734: Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids |
|
|
| Recruiting | 2 | 33 | Europe | Epirubicin, Mitomycin, Gemcitabine, Docetaxel | University Hospital Inselspital, Berne, University of Bern, Hospital Centre Biel/Bienne | Bladder Cancer, Non-muscle Invasive | 11/24 | 11/26 | | |
DARLING-02, NCT06107673: Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） |
|
|
| Recruiting | 2 | 144 | RoW | Dalpiciclib, SHR6390, Aromatase inhibitor, AI, Docetaxel injection, Epirubicin Hydrochloride Injection, Cyclophosphamide injection | Hebei Medical University Fourth Hospital | Breast Cancer | 12/24 | 12/25 | | |
NCT05933967: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 31 | RoW | Orelabrutinib+R-CHOP | Shandong Cancer Hospital and Institute, The First Affiliated Hospital of Nanchang University | The First Affiliated Hospital of Nanchang University | 12/24 | 12/26 | | |
VALENTINE, NCT05569811: NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - Trial |
|
|
| Active, not recruiting | 2 | 120 | Europe | Patritumab deruxtecan, Chemotherapy, Letrozole | SOLTI Breast Cancer Research Group, Daiichi Sankyo, Inc. | Breast Cancer | 03/25 | 07/30 | | |
NCT05834582: Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Fluzoparib+Paclitaxel, Epirubicin+Cyclophosphamide | The First Affiliated Hospital with Nanjing Medical University, Jiangsu HengRui Medicine Co., Ltd. | TNBC - Triple-Negative Breast Cancer | 06/25 | 06/26 | | |
NCT05975151: Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 63 | RoW | Pseudomonas aeruginosa | Qilu Hospital of Shandong University | Bladder Cancer | 08/25 | 12/25 | | |
NCT04437160: Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy |
|
|
| Recruiting | 2 | 286 | RoW | Epirubicin or Pirarubicin, EPI or THP, Cyclophosphamide, CTX | Chinese Academy of Medical Sciences | Triple Negative Breast Cancer | 01/26 | 12/27 | | |
ChiCTR1900021068: A randomized, open label, multicenter, phase II study for comparing docetaxel + carboplatin + trastuzumab versus docetaxel + trastuzumab sequential epirubicin + cyclophosphamide + trastuzumab in the neoadjuvant therapy of patient with early or locally advanced HER2 positive mammary glands cancer |
|
|
| Not yet recruiting | 2 | 296 | | (Docetaxel + carboplatin + trastuzumab) * 6 cycles ;Docetaxel + trastuzumab - epirubicin + cyclophosphamide + trastuzumab | Henan Cancer Hospital; He'nan Cancer Hospital, Self financing | Breast cancer | | | | |
ARIADNE, NCT05900206: Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer |
|
|
| Recruiting | 2 | 370 | Europe | Trastuzumab deruxtecan, T-DXd, Enhertu, Docetaxel, Paclitaxel, Carboplatin, Trastuzumab, Herceptin, Pertuzumab, PErjeta, Ribociclib, Kisqali, Letrozole, Epirubicin, Cyclophosphamide | Karolinska University Hospital | Breast Cancer | 04/27 | 04/32 | | |
ChiCTR1900022293: A multi-center prospective single-arm trial for neoadjuvant chemotherapy with pyrotinib plus trastuzumab for HER2-positive breast cancer |
|
|
| Recruiting | 2 | 174 | | epirubicin, cyclophosphamide, pyrotinib and trastuzumab | First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University, CSCO Hengrui Cancer Research Foundation | Breast Cancer | | | | |
NCT05983094: Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer |
|
|
| Not yet recruiting | 2 | 181 | RoW | Utidelone, Carboplatin, Epirubicin, Trastuzumab, Pertuzumab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences Cancer Hospital，Shanxi Center, Chinese Academy of Medical Sciences Cancer Hospital，Shenzhen Center, First Affiliated Hospital of China Medical University | Breast Cancer, Neoadjuvant Therapy | 09/26 | 09/27 | | |
NCT05862610: The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC |
|
|
| Not yet recruiting | 2 | 150 | NA | Trilaciclib plus chemotherapy, Trilaciclib+AC-T, Chemotherapy, AC-T | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Neoplasm | 12/26 | 06/27 | | |
SMA-BC-002, NCT05978648: Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy |
|
|
| Recruiting | 2 | 116 | RoW | Trilaciclib, COSELA®, G1T28, Epirubicin, Cyclophosphamide, Paclitaxel, Docetaxel, Carboplatin, Trastuzumab, Pertuzumab | wang shusen | Breast Neoplasms | 12/26 | 12/27 | | |
| Active, not recruiting | 2 | 366 | Europe, RoW | Palbociclib, Docetaxel / cyclophosphamide, doxorubicin/cyclophosphamide, epirubicin/cyclophosphamide, paclitaxel | European Organisation for Research and Treatment of Cancer - EORTC, Pfizer, Swedish Association of Breast Oncologists, ETOP IBCSG Partners Foundation, German Adjuvant Breast Cancer Group, SOLTI Breast Cancer Research Group, UNICANCER, Gruppo Oncologico Italiano di Ricerca Clinica, Breast International Group | Breast Cancer Stage II, Breast Cancer Stage III | 06/26 | 09/32 | | |
NCT03286634: ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 |
|
|
| Recruiting | 2 | 60 | Japan, RoW | Daunorubicin, DNR, Prednisolone, Pred, Vincristine, VCR, Epirubicin, EPI, E-coli L-asparaginase, E-coli L-Asp, 6-Mercaptopurine, 6-MP, Methotrexate, MTX, Hydrocortisone, Cytarabine, Ara-C, Cyclophosphamide, Cy | National Hospital Organization Nagoya Medical Center | Down Syndrome, Acute Lymphoblastic Leukemia, Childhood Cancer | 03/28 | 03/33 | | |
ACTRN12616001112459: Study comparing the Efficacy and Safety of FOLFIRINOX ( Fluoropyrimidine, Oxaliplatin and Irinotecan) as Chemotherapy regimen For Resectable Gastric Or Gastroesophageal Junction Cancer to ECF (Cisplatin, Epirubicin and Fluoropyrimidine) as chemotherapy regimen which is the standard treatment |
|
|
| Recruiting | 1/2 | 202 | | | Royal Adelaide Hospital, Royal adelaide hospital | Resectable gastroesophageal junction adenocarcinoma , Resectable gastric adenocarcinoma. | | | | |
